UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
August 31, 2020
Date of Report (Date of earliest event reported)
ETON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-38738 | 37-1858472 | ||
| (State of | (Commission | (I.R.S. Employer | ||
| incorporation) | File Number) | Identification Number) |
21925 W. Field Parkway, Suite 235
Deer Park, Illinois 60010-7208
(Address of principal executive offices) (Zip code)
(847) 787-7361
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| Common Stock, par value $0.001 per share | ETON | NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item 8.01 Other Events.
On August 31, 2020, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that Ingrid Hoos had joined the Company as its Senior Vice President of Scientific Affairs. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
Exhibit 99.1 Press Release dated August 31, 2020
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 31, 2020 | By: | /s/ W. Wilson Troutman |
| W. Wilson Troutman | ||
| Chief Financial Officer and Secretary | ||
| (Principal Financial Officer) |
| 3 |
Exhibit 99.1
Eton Pharmaceuticals Announces Appointment of Ingrid Hoos as Senior Vice President of Scientific Affairs
DEER
PARK, Ill., Aug 31, 2020 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company
focused on developing and commercializing innovative drug products, today announced that it has appointed Ingrid Hoos as the company’s
new Senior Vice President of Scientific Affairs. In the new role, Ms. Hoos will support the company’s regulatory, product
development, and quality activities.
Ms. Hoos joins Eton after spending nine years as Vice President of Regulatory Affairs at Horizon Therapeutics. At Horizon, Ms. Hoos was responsible for the company’s regulatory strategy and regulatory operations. During her tenure, Horizon’s portfolio grew from one FDA-approved product to ten FDA-approved products. Prior to Horizon Therapeutics, Ingrid held leadership roles in regulatory, quality, and product development at Baxter Healthcare, Takeda Pharmaceuticals, and G.D. Searle (now Pfizer).
“We are pleased to have Ingrid joining the team. Ingrid has an impressive track record of successfully working with the FDA to gain approval of complex products, and she has first-hand experience growing an industry leading pharmaceutical company,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
Ingrid Hoos added, “I am excited to join Eton at such a critical point in its history and to have the opportunity to be part of another young and rapidly growing pharmaceutical company. I look forward to immediately working towards gaining FDA-approval of Eton’s pipeline products.”
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing pediatric rare disease products. The company’s first commercial product, Biorphen, is the only FDA approved ready-to-use formulation of phenylephrine injection and was launched in December 2019. The company’s lead pediatric product is the orphan drug Alkindi® Sprinkle, which is currently under review with the FDA. The company has an additional seven products under development, including five that are under review with the FDA.
Company Contact:
David
Krempa
dkrempa@etonpharma.com
612-387-3740